Brief Title
Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy
Official Title
Identification of Mechanisms in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy
Brief Summary
The study aims to evaluate the molecular mechanism underlying the erythroid response observed in some patients with myelodysplasia, myelofibrosis and aplastic anemia treated with Deferasirox or Deferoxamina.
Study Type
Observational
Primary Outcome
To assess the molecular mechanism underlying the erythroid response
Condition
Myelodysplasia
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
100
Start Date
May 2013
Completion Date
December 2019
Primary Completion Date
July 2018
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 18 and older 2. Diagnosis of Myelodysplasia, myelofibrosis or aplastic anemia 3. transfusion-dependent anemia undergoing chelation therapy with deferasirox or deferoxamine Exclusion Criteria: - none
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Daniela Cilloni, MD, ,
Location Countries
Italy
Location Countries
Italy
Administrative Informations
NCT ID
NCT01956799
Organization ID
FISM-BIOFER12
Responsible Party
Sponsor
Study Sponsor
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Study Sponsor
Daniela Cilloni, MD, Principal Investigator, AOU S. Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano (TO)
Verification Date
July 2019